Ablynx raises $200m in Nasdaq listing after drug success
Ablynx, the Belgian biopharmaceutical firm, has raised $200m through a second listing in the US, following positive momentum in the development of a new drug designed to combat a life-threatening blood clotting disorder.
Ablynx issued 11.4m of new American Depositary Shares, listed on Nasdaq and offered to investors in the US and Canada. The ADSs represent one ordinary share each.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org